Document is current
Any future updates will be listed below
-
Authors
Pabla, Sarabjot
Seager, R. J.
Van Roey, Erik
Gao, Shuang
Hoefer, Carrie
Nesline, Mary K.
DePietro, Paul
Burgher, Blake
Andreas, Jonathan
Giamo, Vincent
Wang, Yirong
Lenzo, Felicia L.
Schoenborn, Margot
Zhang, Shengle
Klein, Roger
Glenn, Sean T.
Conroy, Jeffrey M. https://orcid.org/0000-0003-1764-9706
-
Funding
Funding for this research was provided by:
OmniSeq, Inc.
- License Information
-
More Information
Article History
Received: 9 April 2021
Accepted: 14 June 2021
First Online: 7 July 2021
Declarations
:
: Existing de-identified specimens and associated clinical data was submitted to OmniSeq from Roswell Park Comprehensive Cancer Center (Buffalo, NY), Dartmouth-Hitchcock Medical Center (Lebanon, NH), Northwest Oncology (Munster, IN), Hospital Universitario Virgen Macarena (Sevilla, Spain), Duke Cancer Institute (Durham, North Carolina), Mission Health (Ashville, North Carolina), Meharry Medical College (Nashville, Tennessee), Columbia University (New York, NY), Miami Cancer Institute (Miami, FL), University of California, Irvine (Irvine, California), and Medical College of Wisconsin (Milwaukee, WI) upon IRB approval from each individual institution or consented prospective institutional biobanks at Fox Chase Cancer Center (Philadelphia, PA), and Oregon Health Sciences University (Portland, OR). OmniSeq studies based on de-identified data were considered non-human subjects research under IRB-approved protocol (BDR #080316) at Roswell Park Comprehensive Cancer Center (Buffalo, NY).
: Not applicable.
: All authors are employees of OmniSeq. SP, MKN, PDP, YW, MS, SZ, RK, STG, and JMC hold restricted preferred stock in OmniSeq, Inc. STG and JMC are employees of Roswell Park Comprehensive Cancer Center (Buffalo, NY). Roswell Park Comprehensive Cancer Center is a preferred shareholder of OmniSeq, Inc.
